6278

531146

MEDICAMEQ

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

MEDICAMEN BIOTECH LIMITED Share Price Today

MEDICAMEN BIOTECH LIMITED is currently trading at ₹229.55, up by ₹5.65 from the previous close. The stock touched an intraday high of ₹231.05 and a low of ₹224.35 during the latest trading session. Over the past one year, MEDICAMEN BIOTECH LIMITED has delivered a loss of 45.4%, while the stock has declined 21.09% in the last one month.

MEDICAMEN BIOTECH LIMITED performance

Today’s low Today’s high
₹ 224.35 ₹ 231.05
₹ 231.05
52 week low 52 week high
₹ 216.95 ₹ 447.65
₹ 231.05
Open Price ₹ 224.35
Prev. Close ₹ 223.90
Volume (Shares) 7210.00
Total traded value ₹ 16.65
Upper Circuit ₹ 268.65
Lower Circuit ₹ 179.15
info

Investment Returns

Over 1 Month -21.09% Over 3 Months -20.79% Over 6 Months -41.19% Over 1 Year -45.40%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

MEDICAMEN BIOTECH LIMITED fundamentals


  • Market cap (Cr) 312.00
  • P/E Ratio (TTM) 32.52
  • Beta 1.08
  • Book Value / share 206.24
  • Return on equity 4.43%
  • EPS (TTM) 6.94
  • Dividend yield 0.44%
  • Net profit/quarter (Cr) 2.97
info icon alternate text
  • Market cap (Cr) 315.20
  • P/E Ratio (TTM) 32.52
  • Beta 0.92
  • Book Value / share 206.24
  • Return on equity 4.43%
  • EPS (TTM) 6.94
  • Dividend yield 0.44%
  • Net profit/quarter (Cr) 2.97
info icon alternate text

MEDICAMEN BIOTECH LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 54.68
Operating Expense 52.88
Net Profit 2.97
Net Profit Margin (%) 5.43
Earnings Per Share (EPS) 2.19
EBITDA 5.85
Effective Tax Rate (%) 15.86
Particulars DEC 2025 (Values in Cr)
Revenue 43.49
Operating Expense 40.94
Net Profit 2.59
Net Profit Margin (%) 5.95
Earnings Per Share (EPS) 1.91
EBITDA 5.61
Effective Tax Rate (%) 15.90
Particulars SEP 2025 (Values in Cr)
Revenue 42.23
Operating Expense 39.83
Net Profit 2.21
Net Profit Margin (%) 5.23
Earnings Per Share (EPS) 1.63
EBITDA 5.42
Effective Tax Rate (%) 20.21
Particulars JUN 2025 (Values in Cr)
Revenue 38.45
Operating Expense 36.75
Net Profit 1.64
Net Profit Margin (%) 4.26
Earnings Per Share (EPS) 1.21
EBITDA 4.50
Effective Tax Rate (%) 24.42
Particulars MAR 2025 (Values in Cr)
Revenue 26.00
Operating Expense 28.18
Net Profit 2.41
Net Profit Margin (%) 9.26
Earnings Per Share (EPS) 1.90
EBITDA 4.13
Effective Tax Rate (%) 20.72
Particulars MAR 2026 (Values in Cr)
Revenue 178.85
Operating Expense 170.40
Net Profit 9.41
Net Profit Margin (%) 5.26
Earnings Per Share (EPS) 6.94
EBITDA 21.39
Effective Tax Rate (%) 18.52
Particulars MAR 2025 (Values in Cr)
Revenue 151.46
Operating Expense 144.92
Net Profit 9.45
Net Profit Margin (%) 6.23
Earnings Per Share (EPS) 7.43
EBITDA 22.78
Effective Tax Rate (%) 26.07
Particulars MAR 2024 (Values in Cr)
Revenue 172.39
Operating Expense 157.79
Net Profit 13.30
Net Profit Margin (%) 7.71
Earnings Per Share (EPS) 10.50
EBITDA 28.28
Effective Tax Rate (%) 21.25
Particulars MAR 2023 (Values in Cr)
Revenue 137.88
Operating Expense 123.01
Net Profit 15.00
Net Profit Margin (%) 10.87
Earnings Per Share (EPS) 12.04
EBITDA 26.60
Effective Tax Rate (%) 13.44
Particulars MAR 2022 (Values in Cr)
Revenue 115.45
Operating Expense 99.06
Net Profit 14.91
Net Profit Margin (%) 12.91
Earnings Per Share (EPS) 12.20
EBITDA 25.27
Effective Tax Rate (%) 17.67
Particulars MAR 2025 (Values in Cr)
Book Value / Share 167.57
ROE % 3.12
ROCE % 5.56
Total Debt to Total Equity 0.15
EBITDA Margin 12.72
Particulars MAR 2024 (Values in Cr)
Book Value / Share 162.79
ROE % 4.74
ROCE % 8.14
Total Debt to Total Equity 0.14
EBITDA Margin 14.41
Particulars MAR 2023 (Values in Cr)
Book Value / Share 150.82
ROE % 8.67
ROCE % 10.36
Total Debt to Total Equity 0.15
EBITDA Margin 19.02
Particulars MAR 2022 (Values in Cr)
Book Value / Share 119.89
ROE % 10.67
ROCE % 12.27
Total Debt to Total Equity 0.16
EBITDA Margin 22.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 108.78
ROE % 9.55
ROCE % 12.49
Total Debt to Total Equity 0.12
EBITDA Margin 18.12
Particulars MAR 2025 (Values in Cr)
Book Value / Share 171.17
ROE % 4.43
ROCE % 6.71
Total Debt to Total Equity 0.13
EBITDA Margin 15.41
Particulars MAR 2024 (Values in Cr)
Book Value / Share 164.54
ROE % 6.60
ROCE % 9.76
Total Debt to Total Equity 0.14
EBITDA Margin 17.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 152.30
ROE % 8.78
ROCE % 10.45
Total Debt to Total Equity 0.15
EBITDA Margin 19.64
Particulars MAR 2022 (Values in Cr)
Book Value / Share 121.18
ROE % 10.56
ROCE % 12.17
Total Debt to Total Equity 0.16
EBITDA Margin 22.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 109.98
ROE % 9.73
ROCE % 12.62
Total Debt to Total Equity 0.12
EBITDA Margin 18.87
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3.75
Total Assets 297.15
Total Liabilities 297.15
Total Equity 213.05
Share Outstanding 1
Price to Book Ratio 2.81
Return on Assets (%) 2.39
Return on Capital (%) 2.89
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 14.78
Total Assets 294.55
Total Liabilities 294.55
Total Equity 206.98
Share Outstanding 1
Price to Book Ratio 2.33
Return on Assets (%) 3.71
Return on Capital (%) 4.6
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 20.77
Total Assets 278.51
Total Liabilities 278.51
Total Equity 193.41
Share Outstanding 1
Price to Book Ratio 4.30
Return on Assets (%) 5.32
Return on Capital (%) 6.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.82
Total Assets 225.69
Total Liabilities 225.69
Total Equity 146.46
Share Outstanding 1
Price to Book Ratio 5.31
Return on Assets (%) 6.60
Return on Capital (%) 8.72
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.89
Total Assets 193.72
Total Liabilities 193.72
Total Equity 132.88
Share Outstanding 1
Price to Book Ratio 4.86
Return on Assets (%) 6.26
Return on Capital (%) 8.07
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3.58
Total Assets 293.18
Total Liabilities 293.18
Total Equity 217.63
Share Outstanding 1
Price to Book Ratio 2.81
Return on Assets (%) 3.22
Return on Capital (%) 3.86
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 14.62
Total Assets 294.21
Total Liabilities 294.21
Total Equity 209.20
Share Outstanding 1
Price to Book Ratio 2.33
Return on Assets (%) 4.51
Return on Capital (%) 5.57
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 20.44
Total Assets 276.78
Total Liabilities 276.78
Total Equity 193.79
Share Outstanding 1
Price to Book Ratio 4.30
Return on Assets (%) 5.42
Return on Capital (%) 6.88
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.81
Total Assets 225.69
Total Liabilities 225.69
Total Equity 148.03
Share Outstanding 1
Price to Book Ratio 5.31
Return on Assets (%) 6.60
Return on Capital (%) 8.65
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.08
Total Assets 192.18
Total Liabilities 192.18
Total Equity 134.35
Share Outstanding 1
Price to Book Ratio 4.86
Return on Assets (%) 6.49
Return on Capital (%) 8.23
Particulars MAR 2025 (Values in Cr)
Net Income 6.55
Cash from Operations -6.80
Cash from Investing -1.39
Cash from Financing -1.47
Net change in Cash -11.02
Free Cash Flow -4.62
Particulars MAR 2024 (Values in Cr)
Net Income 9.49
Cash from Operations -3.67
Cash from Investing -5.56
Cash from Financing 6.31
Net change in Cash -5.99
Free Cash Flow 2.60
Particulars MAR 2023 (Values in Cr)
Net Income 14.72
Cash from Operations -3.16
Cash from Investing -5.88
Cash from Financing 29.12
Net change in Cash 16.95
Free Cash Flow 3.43
Particulars MAR 2022 (Values in Cr)
Net Income 14.89
Cash from Operations 7.30
Cash from Investing -8.47
Cash from Financing 4.29
Net change in Cash -0.06
Free Cash Flow 15.91
Particulars MAR 2021 (Values in Cr)
Net Income 12.12
Cash from Operations 17.23
Cash from Investing -17.81
Cash from Financing 5.83
Net change in Cash 0.79
Free Cash Flow 35.19
Particulars MAR 2025 (Values in Cr)
Net Income 9.44
Cash from Operations -1.28
Cash from Investing -1.72
Cash from Financing -6.68
Net change in Cash -11.04
Free Cash Flow 0.62
Particulars MAR 2024 (Values in Cr)
Net Income 13.29
Cash from Operations 2.81
Cash from Investing -8.71
Cash from Financing 3.13
Net change in Cash -5.82
Free Cash Flow 8.56
Particulars MAR 2023 (Values in Cr)
Net Income 15.00
Cash from Operations -6.62
Cash from Investing -7.54
Cash from Financing 27.66
Net change in Cash 16.62
Free Cash Flow -0.37
Particulars MAR 2022 (Values in Cr)
Net Income 14.90
Cash from Operations 8.01
Cash from Investing -8.47
Cash from Financing 4.39
Net change in Cash 0.73
Free Cash Flow 16.61
Particulars MAR 2021 (Values in Cr)
Net Income 12.48
Cash from Operations 17.43
Cash from Investing -17.81
Cash from Financing 5.68
Net change in Cash 0.85
Free Cash Flow 35.40
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 33.07 13.67 1.60 253.43 23.12 38.85
BLISS GVS PHARMA LTD 423.70 34.28 3.75 4482.28 118.35 462.70
CIPLA LTD. 1376.25 29.21 3.22 111179.71 1165.55 1672.20
FERMENTA BIOTECH LTD. 327.50 14.45 2.37 963.86 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 33.07 23.13 4.26 253.43 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 568.05 25.46 4.43 1642.27 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8304.35 108.45 23.78 20760.88 7630.00 10653.05
BLISS GVS PHARMA LTD 423.70 45.56 3.88 4482.28 118.35 462.70

MEDICAMEN BIOTECH LIMITED shareholding pattern

Holding
59.44%
40.45%
0.09%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

MEDICAMEN BIOTECH LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
230.05 2.74 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 234.70
  • 26 Days 257.70
  • 10 Days 245.00
  • 50 Days 266.20
  • 12 Days 247.90
  • 100 Days 287.40
  • 20 Days 254.90
  • 200 Days 322.10
233.93 PIVOT
First Support 224.07 First Resistance 239.97 Second Support 218.03 Second Resistance 249.83 Third Support 208.17 Third Resistance 255.87
RSI 35.60 ADX 47.35 MACD -8.14 Williams % R -85.39 Commodity Channel Index (CCI) -176.46
Date 2026-06-10 Week 16795.00 Same Day 15251.00 Month 14914.00
1 Year 1.09 3 Year 1.24
Over 1 Month
-21.09% down
Over 1 Year
-45.40% down
Over 3 Months
-20.79% down
Over 3 Years
-29.70% down
Over 6 Months
-41.19% down
Over 5 Years
-16.05% down

MEDICAMEN BIOTECH LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2025 1.0 Final 19 Sep 2025 Equity shares
19 Sep 2024 1.0 Final 19 Sep 2024 Equity shares
20 Sep 2023 1.0 Final 21 Sep 2023 Equity shares
19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
16 Sep 2021 1.0 Final 19 Sep 2021 Equity shares
17 Sep 2020 0.5 Final 19 Sep 2020 Equity shares
17 Sep 2019 1.0 Final 18 Sep 2019 Equity shares
08 Aug 2017 1.0 Interim 09 Aug 2017 Equity shares
21 Sep 2010 0.75 Final 23 Sep 2010 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2025 1.0 Final 19 Sep 2025 Equity shares
19 Sep 2024 1.0 Final 19 Sep 2024 Equity shares
20 Sep 2023 1.0 Final 21 Sep 2023 Equity shares
19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
16 Sep 2021 1.0 Final 19 Sep 2021 Equity shares
17 Sep 2020 0.5 Final 19 Sep 2020 Equity shares
17 Sep 2019 1.0 Final 18 Sep 2019 Equity shares
08 Aug 2017 1.0 Interim 09 Aug 2017 Equity shares
21 Sep 2010 0.75 Final 23 Sep 2010 Equity shares

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Medicamen Biotech Ltd?

Answer Field

Medicamen Biotech Ltd share price is for NSE ₹ 229.55 & for BSE ₹ 229.20 as on Jun 12 2026 03:30 PM.

What is the Market Cap of Medicamen Biotech Ltd Share?

Answer Field

The market cap of Medicamen Biotech Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 12 2026 03:30 PM.

What is the 52 Week High and Low of Medicamen Biotech Ltd?

Answer Field

The 52 Week High and Low of Medicamen Biotech Ltd for NSE is ₹ 447.65 and ₹ 216.95 and for BSE is ₹ 454.00 and ₹ 217.65.

What is 1 year return for Medicamen Biotech Ltd?

Answer Field

The 1 year returns on the stock has been -47.31%.

What is the P/E Ratio of Medicamen Biotech Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM the price-to-earnings (PE) ratio for Medicamen Biotech Ltd share is 32.52.

What is the PB ratio of Medicamen Biotech Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM, the price-to-book (PB) ratio for Medicamen Biotech Ltd share is 206.24.

How to Buy Medicamen Biotech Ltd Share?

Answer Field

You can trade in Medicamen Biotech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Medicamen Biotech Ltd Share on Bajaj Broking App?

Answer Field

To buy Medicamen Biotech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Medicamen Biotech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|